World Health Organization Raises Alert Over Severe Shortage of Obesity Jabs
Under 10% of individuals who could benefit from obesity jabs such as Wegovy are able to get them, caution the WHO as it publishes its inaugural advice on the medications.
Considering more than one billion people worldwide now living with obesity, it is calling for more widespread and fairer access to this class of drugs.
According to projections, in excess of 2,000,000,000 are projected to be obese by 2030 unless action is taken.
"Our latest guidance affirms that obesity is a long-term condition that can be addressed with comprehensive and ongoing care," said WHO director-general Tedros Adhanom Ghebreyesus.
Significant expense, constrained manufacturing, and supply-chain constraints are key barriers to broad access to the injections that can help people shift substantial body mass, explains the body.
GLP-1 Therapy Shortage
Even under the present most favorable case, the manufacturing of such drugs could only cover about 100 million people – under 10% of eligible patients, as stated by the health organization.
The advice urges countries and companies to expand availability, via strategies like licensing agreements.
Exclusive production rights on the active ingredient – the main ingredient of the drug Wegovy – is due to expire in several nations in 2026.
How Obesity Drugs Operate
The injections replicate a biological compound to delay gastric emptying, reduce hunger and increase satiety so people consume fewer calories.
Patients commonly see weight reduction in the initial weeks of beginning the regular doses.
Studies indicates patients may regain a significant portion a year later of halting the drug, because their usual food cravings resume.
To be overweight or obese raises your chance for contracting health problems, like diabetes, cardiovascular issues, stroke, and some malignancies.
Excess weight impacts individuals in countries worldwide and was associated with over three and a half million fatalities worldwide in 2024, as per the WHO.